The involvement of NK cell activation following intranasal administration of CpG DNA lipoplex in the prevention of pulmonary metastasis and peritoneal dissemination in mice

Clinical and Experimental Metastasis

Volumn 29, Issue 1, 2012, Pages 63-70

  Zhou, Shuwen ^a,b   Kawakami, Shigeru ^a   Higuchi, Yuriko ^a   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

CpG DNA; Intranasal; Liposomes; NK cells; Peritoneal dissemination; Pulmonary metastasis

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; LIPOPLEX; DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERITONEUM METASTASIS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CPG ISLAND; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG TUMOR; MACROPHAGE ACTIVATION; METASTASIS; NUCLEOTIDE SEQUENCE; PERITONEUM TUMOR;

ADMINISTRATION, INTRANASAL; ANIMALS; BASE SEQUENCE; CPG ISLANDS; DNA; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MACROPHAGE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PERITONEAL NEOPLASMS;

EID: 84855998783     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9429-1     Document Type: Article

References (34)

1. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760 (Pubitemid 34293438)
2. Krieg AM (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27(2):161-167
3. Nierkens S, den Brok MH, Roelofsen T et al (2009) Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One 4(12): e8368
4. Kuramoto Y, Kawakami S, Zhou S et al (2008) Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. J Control Release 126(3):274-280
5. Kuramoto Y, Kawakami S, Zhou S et al (2009) Mannosylated cationic liposomes/CpG DNA complex for the treatment of hepatic metastasis after intravenous administration in mice. J Pharm Sci 98(3):1193-1197
6. Ugwoke MI, Agu RU, Verbeke N et al (2005) Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 57(11):1640-1665 (Pubitemid 41443473)
7. Almeida AJ, Alpar HO (1996) Nasal delivery of vaccines. J Drug Target 3:455-467 (Pubitemid 26280642)
8. Zhou S, Kawakami S, Yamashita F et al (2010) Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Lett 287(1):75-81
9. Schantz SP, Brown BW, Lira E et al (1987) Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer. Cancer Immunol Immunother 25:141-148
10. Vivier E, Tomasello E, Baratin M et al (2008) Functions of natural killer cells. Nat Immunol 9(5):503-510 (Pubitemid 351560519)
11. Siveen KS, Kuttan G (2009) Role of macrophages in tumour progression. Immunol Lett 123(2):97-102
12. Moldoveanu Z, Love-Homan L, Huang WQ et al (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16(11-12):1216-1224 (Pubitemid 28307893)
13. Pum PB, Bhat AA, Mohan T et al (2009) Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. Int Immunopharmacol 9(4):468-477
14. Corbctt TH, Griswold Jr, Robcrts BJ et al (1975) Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays with a note on carcinogen structure. Cancer Res 35(9):2434-2439
15. Hyoudou K, Nishikawa M, Umeyama Y et al (2004) Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells. Clin Cancer Res 10(22):7685-7691 (Pubitemid 39557533)
16. Kawakami S, Sato A, Nishikawa M et al (2000) Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther 7(4):292-299 (Pubitemid 30119732)
17. Kuramoto Y, Nishikawa M, Hyoudou K et al (2006) Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J Control Release 115(2):226-233 (Pubitemid 44537504)
18. Wijagkanalan W, Kawakami S, Takenaga M et al (2008) Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J Control Release 125(2):121-130 (Pubitemid 350299608)
19. Yoon TJ, Kim TJ, Lee H et al (2007) Anti-tumor metastatic activity of beta-glucan purified from mutated Saccharomyces cerevisiae. Int Immunopharmacol 8(1):36-42 (Pubitemid 350199098)
20. Saiki I, Saito S, Fujita C et al (1998) Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues. Vaccine 6:238-244
21. Yoon TJ, Yoo YC, Lee SW et al (2004) Anti-metastatic activity of Acanthopanax senticosus extract and its possible immunological mechanism of action. J Ethnopharmacol 93(2-3):247-253 (Pubitemid 38962412)
22. Yoon TJ, Yoo YC, Kang TB et al (1998) Prophylactic effect of Korean mistletoe (Viscum album coloratum) extract on tumor metastasis is mediated by enhancement of NK cell activity. Int J Immunopharmacol 20(4-5):163-172 (Pubitemid 28355938)
23. Kitchens WH, Chase CM, Uehara S et al (2007) Macrophage depletion suppresses cardiac allograft vasculopathy in mice. Am J Transplant 7(12):2675-2682 (Pubitemid 350045773)
24. Gregoire C, Chasson L, Luci C et al (2007) The trafficking of natural killer cells. Immunol Rev 220:169-182 (Pubitemid 350045566)
25. Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47:187-376 (Pubitemid 20010960)
26. Bahjat KS, Prell RA, Allen HE et al (2007) Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease. J Immunol 179(11):7376-7384
27. Sivori S, Falco M, Della Chiesa M et al (2004) CpG and double-stranded RNA trigger human NK cells by toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 101(27):10116-10121 (Pubitemid 38891204)
28. Paget C, Bialecki E, Fontaine J et al (2009) Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides. J Immunol 182(4):1846-1853
29. Lysaght J, Jarnicki AG, Mills KH (2007) Reciprocal effects of Th1 and Treg cell inducing pathogen-associated immunomodulatory molecules on anti-tumor immunity. Cancer Immunol Immunother 56(9):1367-1379 (Pubitemid 47024708)
30. Shindo H, Ogura T, Masuno T et al (1985) Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice. Cancer Immunol Immunother 20(2):145-15025
31. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211-217 (Pubitemid 40568680)
32. Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796(1):11-18
33. Zeisberger SM, Odermatt B, Marty C et al (2006) Clodronate-liposome- mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95:272-281 (Pubitemid 44187587)
34. Suzuki K, Suda T, Naito T et al (2005) Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. Am J Respir Crit Care Med 171(7):707-713 (Pubitemid 40471140)